Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 56424730900
Loop profile: 794855
Scopus Author ID: 58592137200

Countries

Italy

Activities

Collapse all

Employment (4)

Azienda Ospedaliera Pugliese Ciaccio: Catanzaro, IT

2022-01-24 to present
Employment
Source: Self-asserted source
Marco ROSSI

Memorial Sloan-Kettering Cancer Center: New York, NY, US

2002 to 2005 | Research Fellow
Employment
Source: Self-asserted source
Marco ROSSI

Fred Hutchinson Cancer Research Center: Seattle, WA, US

2001 to 2002 | Research Fellow
Employment
Source: Self-asserted source
Marco ROSSI

UniversitĂ  degli Studi di Napoli Federico II: Napoli, Campania, IT

1999 to 2002 | Medico in formazione specialistica disciplina ematologia
Employment
Source: Self-asserted source
Marco ROSSI

Education and qualifications (1)

Universita degli Studi Magna Graecia di Catanzaro: Catanzaro, Calabria, IT

2005 to present | Associate Professor in Hematology (Experimental and Clinical Medicine)
Education
Source: Self-asserted source
Marco ROSSI

Works (50 of 63)

Items per page:
Page 1 of 2

Venetoclax: A Game Changer in the Treatment of Younger AML Patients?

Cancers
2023-12-22 | Journal article
DOI: 10.3390/cancers16010073
Part of ISSN: 2072-6694
Contributors: Matteo Molica; Salvatore Perrone; Vincenzo Federico; Caterina Alati; stefano molica; Marco Rossi
Source: Self-asserted source
Marco ROSSI

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

Cancers
2023-10 | Journal article | Author
DOI: 10.3390/cancers15205060
Contributors: Matteo Molica; Salvatore Perrone; Costanza Andriola; Marco ROSSI
Source: check_circle
Multidisciplinary Digital Publishing Institute

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat <i>FLT3</i>-Mutated AML Patients

Journal of Clinical Medicine
2023-05 | Journal article | Author
DOI: 10.3390/jcm12113647
Contributors: Matteo Molica; Salvatore Perrone; Marco ROSSI
Source: check_circle
Multidisciplinary Digital Publishing Institute

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells

Cancers
2022-06 | Journal article | Author
DOI: 10.3390/cancers14122886
Contributors: Caterina Riillo; Daniele Caracciolo; Katia Grillone; Nicoletta PolerĂ ; Franca Maria Tuccillo; Patrizia Bonelli; Giada Juli; Serena Ascrizzi; Francesca Scionti; mariamena arbitrio et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report

Therapeutic Advances in Chronic Disease
2022-01 | Journal article
DOI: 10.1177/20406223211063024
Part of ISSN: 2040-6223
Part of ISSN: 2040-6231
Contributors: Maria d'Apolito; Rocco Spagnuolo; Maria Anna Siciliano; Vito Barbieri; Cristina Cosco; Lucia Fiorillo; Onofrio Cuomo; Valeria ZuccalĂ ; Pierpaolo Correale; Licia Pensabene et al.
Source: Self-asserted source
Marco ROSSI

A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant

Annals of Hematology
2020 | Journal article
DOI: 10.1007/s00277-019-03901-w
EID:

2-s2.0-85076913559
Contributors: Martino, M.; Gori, M.; Tripepi, G.; Recchia, A.G.; Cimminiello, M.; Provenzano, P.F.; Naso, V.; Ferreri, A.; Moscato, T.; Console, G. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

The non-coding RNA landscape of plasma cell dyscrasias

Cancers
2020 | Journal article
DOI: 10.3390/cancers12020320
EID:

2-s2.0-85079071982
Contributors: Morelli, E.; GullĂ , A.; Rocca, R.; Federico, C.; Raimondi, L.; Malvestiti, S.; Agosti, V.; Rossi, M.; Costa, G.; Giavaresi, G. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology

Non-Coding RNA
2020-09 | Journal article | Author
DOI: 10.3390/ncrna6030037
Contributors: Lavinia Raimondi; Angela De Luca; Gianluca Giavaresi; Stefania RAIMONDO; Alessia Gallo; Elisa Taiana; Riccardo Alessandro; Marco ROSSI; Antonino Neri; Giuseppe Viglietto et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Anti-tumor activity and epigenetic impact of the polyphenol oleacein in multiple myeloma

Cancers
2019 | Journal article
DOI: 10.3390/cancers11070990
EID:

2-s2.0-85071176599
Contributors: Juli, G.; Oliverio, M.; Bellizzi, D.; Cantafio, M.E.G.; Grillone, K.; Passarino, G.; Colica, C.; Nardi, M.; Rossi, M.; Procopio, A. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

miR-22 suppresses DNA ligase III addiction in multiple myeloma

Leukemia
2019 | Journal article
DOI: 10.1038/s41375-018-0238-2
EID:

2-s2.0-85052535560
Contributors: Caracciolo, D.; Di Martino, M.T.; Amodio, N.; Morelli, E.; Montesano, M.; Botta, C.; Scionti, F.; Talarico, D.; Altomare, E.; Gallo Cantafio, M.E. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials

Expert Review of Hematology
2019 | Journal article
DOI: 10.1080/17474086.2019.1634541
EID:

2-s2.0-85070096109
Contributors: Martino, M.; Rossi, M.; Ferreri, A.; Loteta, B.; Morabito, A.; Moscato, T.; Console, G.; Innao, V.; Naso, V.; Provenzano, P.F. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma

Cancers
2019 | Journal article
DOI: 10.3390/cancers11020236
EID:

2-s2.0-85063586909
Contributors: Amodio, N.; Cantafio, M.E.G.; Botta, C.; Agosti, V.; Federico, C.; Caracciolo, D.; Ronchetti, D.; Rossi, M.; Driessen, C.; Neri, A. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma

Journal of Hematology and Oncology
2019 | Journal article
DOI: 10.1186/s13045-019-0714-9
EID:

2-s2.0-85063320533
Contributors: Cucè, M.; Gallo Cantafio, M.E.; Siciliano, M.A.; Riillo, C.; Caracciolo, D.; Scionti, F.; Staropoli, N.; Zuccalà, V.; Maltese, L.; Di Vito, A. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Depression of lymphocyte activity during cutaneous leishmaniasis: a case report

Diagnostic Microbiology and Infectious Disease
2018 | Journal article
DOI: 10.1016/j.diagmicrobio.2018.05.025
EID:

2-s2.0-85048930464
Contributors: Matera, G.; Torti, C.; Mazzitelli, M.; Greco, G.; Rania, A.; Peronace, C.; Settembre, P.; Galati, L.; Giancotti, A.; Lamberti, A.G. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity

Leukemia
2018 | Journal article
DOI: 10.1038/s41375-018-0067-3
EID:

2-s2.0-85042559590
Contributors: Amodio, N.; Stamato, M.A.; Juli, G.; Morelli, E.; Fulciniti, M.; Manzoni, M.; Taiana, E.; Agnelli, L.; Cantafio, M.E.G.; Romeo, E. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

MIR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells

Leukemia
2018 | Journal article
DOI: 10.1038/leu.2017.336
EID:

2-s2.0-85044673831
Contributors: Botta, C.; Cucè, M.; Pitari, M.R.; Caracciolo, D.; Gullà, A.; Morelli, E.; Riillo, C.; Biamonte, L.; Gallo Cantafio, M.E.; Prabhala, R. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Mouse models of multiple myeloma: Technologic platforms and perspectives

Oncotarget
2018 | Journal article
DOI: 10.18632/oncotarget.24614
EID:

2-s2.0-85045344367
Contributors: Rossi, M.; Botta, C.; Arbitrio, M.; Grembiale, R.D.; Tagliaferri, P.; Tassone, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Blood
2018 | Journal article
DOI: 10.1182/blood-2018-03-836601
EID:

2-s2.0-85050732895
Contributors: Morelli, E.; Biamonte, L.; Federico, C.; Amodio, N.; Di Martino, M.T.; Cantafio, M.E.G.; Manzoni, M.; Scionti, F.; Samur, M.K.; GullĂ , A. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in relapsed/refractory patients

Blood Advances
2017 | Journal article
DOI: 10.1182/bloodadvances.2016003905
EID:

2-s2.0-85037153590
Contributors: Botta, C.; Ciliberto, D.; Rossi, M.; Staropoli, N.; Cucè, M.; Galeano, T.; Tagliaferri, P.; Tassone, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival

Blood cancer journal
2016 | Journal article
DOI: 10.1038/bcj.2016.118
EID:

2-s2.0-85028026063
Contributors: Botta, C.; Di Martino, M.T.; Ciliberto, D.; Cucè, M.; Correale, P.; Rossi, M.; Tagliaferri, P.; Tassone, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients

Leukemia
2016 | Journal article
DOI: 10.1038/leu.2016.245
EID:

2-s2.0-84988345526
Contributors: Mimmi, S.; Vecchio, E.; Iaccino, E.; Rossi, M.; Lupia, A.; Albano, F.; Chiurazzi, F.; Fiume, G.; Pisano, A.; Ceglia, S. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Mir-221/222 are promising targets for innovative anticancer therapy

Expert Opinion on Therapeutic Targets
2016 | Journal article
DOI: 10.1517/14728222.2016.1164693
EID:

2-s2.0-84961392160
Contributors: Di Martino, M.T.; Rossi, M.; Caracciolo, D.; GullĂ , A.; Tagliaferri, P.; Tassone, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts

Oncotarget
2015 | Journal article
DOI: 10.18632/oncotarget.4398
EID:

2-s2.0-84944474390
Contributors: Pitari, M.R.; Rossi, M.; Amodio, N.; Botta, C.; Morelli, E.; Federico, C.; Annamaria GullĂ ; Caracciolo, D.; Martino, M.T.D.; Arbitrio, M. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

MicroRNAs in multiple myeloma and related bone disease

Annals of Translational Medicine
2015 | Journal article
DOI: 10.3978/j.issn.2305-5839.2015.12.13
EID:

2-s2.0-85015503070
Contributors: Rossi, M.; Tagliaferri, P.; Tassone, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

miR-29s: A family of epi-miRNAs with therapeutic implications in hematologic malignancies

Oncotarget
2015 | Journal article
EID:

2-s2.0-84931088607
Contributors: Amodio, N.; Rossi, M.; Raimondi, L.; Pitari, M.R.; Botta, C.; Tagliaferri, P.; Tassone, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

Leukemia
2015 | Journal article
DOI: 10.1038/leu.2015.124
EID:

2-s2.0-84946494986
Contributors: Morelli, E.; Leone, E.; Cantafio, M.E.G.; Di Martino, M.T.; Amodio, N.; Biamonte, L.; GullĂ , A.; Foresta, U.; Pitari, M.R.; Botta, C. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations

BioDrugs
2014 | Journal article
DOI: 10.1007/s40259-014-0100-7
EID:

2-s2.0-84915784738
Contributors: Leporini, C.; Patanè, M.; Saullo, F.; Rende, P.; Gallelli, L.; Paola, E.; Toscano, R.; Lucia, M.; Rossi, M.; Sarro, G. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia

Leukemia and Lymphoma
2014 | Journal article
DOI: 10.3109/10428194.2013.824078
EID:

2-s2.0-84901342580
Contributors: Rossi, M.; Gentile, M.; Toscano, R.; Recchia, A.G.; Bossio, S.; Caruso, N.; De Stefano, L.; Granata, T.; Pellicanò, M.; Vigna, E. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

In vitro and In Vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells

PLoS ONE
2014 | Journal article
DOI: 10.1371/journal.pone.0089659
EID:

2-s2.0-84896119502
Contributors: Di Martino, M.T.; GullĂ , A.; Cantafio, M.E.G.; Altomare, E.; Amodio, N.; Leone, E.; Morelli, E.; Lio, S.G.; Caracciolo, D.; Rossi, M. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

MicroRNA and multiple myeloma: From laboratory findings to translational therapeutic approaches

Current Pharmaceutical Biotechnology
2014 | Journal article
EID:

2-s2.0-84907171169
Contributors: Tassone, P.; Amodio, N.; Di Martino, M.T.; Rossi, M.; Tagliaferri, P.; Tassone, P.; Cho, W.C.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

From target therapy to miRNA therapeutics of human multiple myeloma: Theoretical and technological issues in the evolving scenario

Current Drug Targets
2013 | Journal article
DOI: 10.2174/13894501113149990186
EID:

2-s2.0-84881349597
Contributors: Rossi, M.; Amodio, N.; Di Martino, M.T.; Caracciolo, D.; Tagliaferri, P.; Tassone, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Immunologic microenvironment and personalized treatment in multiple myeloma

Expert Opinion on Biological Therapy
2013 | Journal article
DOI: 10.1517/14712598.2013.799130
EID:

2-s2.0-84879564424
Contributors: Rossi, M.; Botta, C.; Correale, P.; Tassone, P.; Tagliaferri, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells

Cell Cycle
2013 | Journal article
DOI: 10.4161/cc.26585
EID:

2-s2.0-84890290469
Contributors: Amodio, N.; Bellizzi, D.; Leotta, M.; Raimondi, L.; Biamonte, L.; D'Aquila, P.; Di Martino, M.T.; Calimeri, T.; Rossi, M.; Lionetti, M. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease

Journal of Cellular Physiology
2013 | Journal article
DOI: 10.1002/jcp.24306
EID:

2-s2.0-84875538389
Contributors: Rossi, M.; Pitari, M.R.; Amodio, N.; Di Martino, M.T.; Conforti, F.; Leone, E.; Botta, C.; Paolino, F.M.; Del Giudice, T.; Iuliano, E. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials

European Journal of Cancer
2013 | Journal article
DOI: 10.1016/j.ejca.2012.08.019
EID:

2-s2.0-84872677684
Contributors: Ciliberto, D.; Botta, C.; Correale, P.; Rossi, M.; Caraglia, M.; Tassone, P.; Tagliaferri, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth

Clinical Cancer Research
2013 | Journal article
DOI: 10.1158/1078-0432.CCR-12-3325
EID:

2-s2.0-84877100047
Contributors: Leone, E.; Morelli, E.; Di Martino, M.T.; Amodio, N.; Foresta, U.; GullĂ , A.; Rossi, M.; Neri, A.; Giordano, A.; Munshi, N.C. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: Personal experience in a longitudinal study,Risonanza magnetica whole body e TC/PET in pazienti con mieloma multiplo in stadiazione e dopo trattamento: esperienza personale in uno studio longitudinale

Radiologia Medica
2013 | Journal article
DOI: 10.1007/s11547-013-0946-7
EID:

2-s2.0-84890309833
Contributors: Cascini, G.L.; Falcone, C.; Console, D.; Restuccia, A.; Rossi, M.; Parlati, A.; Tamburrini, O.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Canonical and noncanonical hedgehog pathway in the pathogenesis of multiple myeloma

Blood
2012 | Journal article
DOI: 10.1182/blood-2011-07-368142
EID:

2-s2.0-84879165722
Contributors: Blotta, S.; Jakubikova, J.; Calimeri, T.; Roccaro, A.M.; Amodio, N.; Azab, A.K.; Foresta, U.; Mitsiades, C.S.; Rossi, M.; Todoerti, K. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

MiR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

Cell Death and Disease
2012 | Journal article
DOI: 10.1038/cddis.2012.175
EID:

2-s2.0-84870543762
Contributors: Amodio, N.; Di Martino, M.T.; Foresta, U.; Leone, E.; Lionetti, M.; Leotta, M.; GullĂ , A.M.; Pitari, M.R.; Conforti, F.; Rossi, M. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Molecular targets for the treatment of multiple myeloma

Current Cancer Drug Targets
2012 | Journal article
DOI: 10.2174/156800912802429300
EID:

2-s2.0-84866418812
Contributors: Rossi, M.; Di Martino, M.T.; Morelli, E.; Leotta, M.; Rizzo, A.; Grimaldi, A.; Misso, G.; Tassone, P.; Caraglia, M.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Osteonecrosis of the jaw prevention and management in modern oncology

Osteonecrosis: Diagnosis, Treatment and Management
2012 | Book
EID:

2-s2.0-84892796362
Contributors: Rossi, M.; Tagliaferri, P.; Tassone, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Promises and challenges of microRNA-based treatment of multiple myeloma

Current Cancer Drug Targets
2012 | Journal article
DOI: 10.2174/156800912802429355
EID:

2-s2.0-84866410501
Contributors: Tagliaferri, P.; Rossi, M.; Di Martino, M.; Amodio, N.; Leone, E.; GullĂ , A.; Neri, A.; Tassone, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence

Clinical Cancer Research
2012 | Journal article
DOI: 10.1158/1078-0432.CCR-12-1708
EID:

2-s2.0-84869238270
Contributors: Di Martino, M.T.; Leone, E.; Amodio, N.; Foresta, U.; Lionetti, M.; Pitari, M.R.; Gallo Cantafio, M.E.; GullĂ , A.; Conforti, F.; Morelli, E. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: Analysis by DMET microarray profiling

British Journal of Haematology
2011 | Journal article
DOI: 10.1111/j.1365-2141.2011.08622.x
EID:

2-s2.0-79960838263
Contributors: di Martino, M.T.; Arbitrio, M.; Guzzi, P.H.; Leone, E.; Baudi, F.; Piro, E.; Prantera, T.; Cucinotto, I.; Calimeri, T.; Rossi, M. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

Leukemia
2011 | Journal article
DOI: 10.1038/leu.2010.300
EID:

2-s2.0-79954436115
Contributors: Calimeri, T.; Battista, E.; Conforti, F.; Neri, P.; Di Martino, M.T.; Rossi, M.; Foresta, U.; Piro, E.; Ferrara, F.; Amorosi, A. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Peptide-loaded langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo

Clinical Cancer Research
2011 | Journal article
DOI: 10.1158/1078-0432.CCR-10-3421
EID:

2-s2.0-79953324723
Contributors: Romano, E.; Rossi, M.; Ratzinger, G.; De Cos, M.-A.; Chung, D.J.; Panageas, K.S.; Wolchock, J.D.; Houghton, A.N.; Chapman, P.B.; Heller, G. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Translational studies on the bone marrow microenvironment in multiple myeloma: Experimental models and emerging therapeutical strategies

Angiogenesis &amp; Therapeutic Targets In Cancer
2010 | Book
DOI: 10.2174/978160805007911001010165
EID:

2-s2.0-84884424652
Contributors: Tassone, P.; Calimeri, T.; Rossi, M.; Martino, M.T.D.; Neri, P.; Tagliaferri, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Challenging the current approaches to multiple myeloma-related bone disease: From bisphosphonates to target therapy

Current Cancer Drug Targets
2009 | Journal article
DOI: 10.2174/156800909789760393
EID:

2-s2.0-72849146885
Contributors: Tassone, P.; Tagliaferri, P.; Rossi, M.; Calimeri, T.; Bulotta, A.; Abbruzzese, A.; Caraglia, M.; Neri, P.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells

Blood
2009 | Journal article
DOI: 10.1182/blood-2008-11-191197
EID:

2-s2.0-70149093957
Contributors: Chung, D.J.; Rossi, M.; Romano, E.; Ghith, J.; Yuan, J.; Munn, D.H.; Young, J.W.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier

In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor

British Journal of Haematology
2008 | Journal article
DOI: 10.1111/j.1365-2141.2008.07387.x
EID:

2-s2.0-54849407184
Contributors: Neri, P.; Tagliaferri, P.; Di Martino, M.T.; Calimeri, T.; Amodio, N.; Bulotta, A.; Ventura, M.; Eramo, P.O.; Viscomi, C.; Arbitrio, M. et al.
Source: Self-asserted source
Marco ROSSI via Scopus - Elsevier
Items per page:
Page 1 of 2

Peer review (3 reviews for 3 publications/grants)

Review activity for BMC cancer (1)
Review activity for Cells. (1)
Review activity for Molecular medicine. (1)
How many people are using ORCID?